# New Adeno-Associated Virus Capsids for Gene Therapy

> This patent describes new types of adeno-associated virus (AAV) capsids and how to use them in cells to deliver genes for therapies or vaccines.

- **Patent:** US 11357868
- **Original title:** Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor
- **Owner:** University of Pennsylvania
- **Granted:** 2022
- **Status:** Active
- **Times cited:** 1
- **Field:** biotech, pharmaceutical, gene_editing

## What it does

This patent is about creating specialized tools for gene therapy. It claims specific versions of adeno-associated virus (AAV) capsids, which are like protective shells for delivering genetic material. Specifically, it describes cultured host cells that contain engineered DNA (recombinant nucleic acid molecules) designed to produce these new AAV capsids, named AAVhu37. These DNA molecules also carry a gene that is not from AAV (a heterologous non-AAV sequence), intended for therapeutic use. The patent details how these engineered cells, when containing specific parts of the AAVhu37 capsid protein sequence (like vp1, vp2, or vp3) and a 'rep gene' (which helps the virus replicate), can be used to produce gene therapy vectors. For example, a cell might be engineered with a plasmid containing the DNA for the AAVhu37 vp1 capsid protein and a therapeutic gene, along with a rep gene from AAV2.

## What it does NOT cover

- Does not cover AAV capsids that do not use the specific AAVhu37 sequences defined in the claims.
- Does not cover the use of these AAV vectors in a living organism, only in cultured host cells.
- Does not cover the rep gene being from a source other than AAV2 if claim 3, 6, or 9 is considered.
- Does not cover the recombinant nucleic acid molecule being something other than a plasmid.
- Does not cover the heterologous non-AAV sequence being identical to an AAV sequence.

## The clever bit

The innovation lies in identifying and defining specific novel sequences for AAV capsid proteins (AAVhu37) that can be engineered into vectors for gene delivery. This allows for potentially more targeted or efficient delivery of therapeutic genes compared to previously known AAV types.

## Real-world examples

1. Research laboratories developing gene therapy vectors
2. Biotechnology companies creating new treatments for genetic diseases

## Why it matters

Adeno-associated viruses (AAVs) are crucial for gene therapy because they can deliver genetic material to target cells without causing disease. Developing new AAV variants with improved properties, like better delivery efficiency or reduced immune response, is key to advancing the field. This patent contributes to that effort by providing novel AAV capsid sequences that researchers can use to create more effective gene therapies.

## Frequently asked questions

### What does New Adeno-Associated Virus Capsids for Gene Therapy cover?

This patent describes new types of adeno-associated virus (AAV) capsids and how to use them in cells to deliver genes for therapies or vaccines.

### Who owns patent US 11357868?

University of Pennsylvania owns this patent, granted in 2022.

### When does this patent expire?

This patent is expected to expire on October 12, 2041, when the invention enters the public domain.

### What is patent US 11357868 cited by?

This patent has been cited by 1 later patents that build on its ideas.

### What problem does this patent solve?

Adeno-associated viruses (AAVs) are crucial for gene therapy because they can deliver genetic material to target cells without causing disease. Developing new AAV variants with improved properties, like better delivery efficiency or reduced immune response, is key to advancing the field. This patent contributes to that effort by providing novel AAV capsid sequences that researchers can use to create more effective gene therapies.

### What does this patent NOT cover?

Does not cover AAV capsids that do not use the specific AAVhu37 sequences defined in the claims.

**Full plain-English explainer:** https://patentbrief.org/patent/us/11357868/adeno-associated-virus-aav-clades-sequences-vectors-containing-same-and-uses-the

**Original patent:** https://patents.google.com/patent/US11357868

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._


## Related patents

Semantically similar inventions in the PatentBrief corpus:

- [Engineering Cells to Make Gene Therapy Viruses Using AAVrh.10](https://patentbrief.org/patent/us/11499167/method-of-detecting-andor-identifying-adeno-associated-virus-aav-sequences-and-i) — This patent describes specific engineered cells that contain parts of the AAVrh.10 virus and an additional non-viral genetic sequence, designed to produce gene therapy vectors.
- [Engineered AAV Vectors for Targeted Gene Delivery to Specific Body Parts](https://patentbrief.org/patent/us/12735721/engineered-adeno-associated-aav-vectors-for-transgene-expression) — This patent describes specially designed adeno-associated virus (AAV) vectors that can deliver new genetic material to specific tissues in the body, such as the brain, heart, or retina, to treat diseases.
- [Treating Muscular Dystrophy with a Self-Complementary AAV Gene Therapy](https://patentbrief.org/patent/us/12735723/self-complementary-adeno-associated-virus-vector-and-its-use-in-treatment-of) — This patent describes a method to treat muscular dystrophy by delivering a specific gene using a specially designed, self-complementary adeno-associated virus (AAV) vector.
- [Delivering Large Gene Editing Tools into Cells with Hybrid Virus-Lipid Packages](https://patentbrief.org/patent/us/12350368/delivery-of-large-payloads) — This patent describes a sophisticated delivery system that combines parts of a virus with a fat bubble (liposome) to efficiently transport large molecules, like CRISPR gene-editing components, into specific cells.
- [How to Edit Genes in Human Cells Using an Engineered CRISPR System](https://patentbrief.org/patent/us/8697359/crispr-gene-editing) — This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
